1. Home
  2. AHG vs MGTX Comparison

AHG vs MGTX Comparison

Compare AHG & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AHG

Akso Health Group ADS

HOLD

Current Price

$1.60

Market Cap

1.1B

ML Signal

HOLD

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

HOLD

Current Price

$12.56

Market Cap

909.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AHG
MGTX
Founded
2013
2015
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
909.1M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
AHG
MGTX
Price
$1.60
$12.56
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$24.57
AVG Volume (30 Days)
10.9K
1.2M
Earning Date
08-14-2025
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.02
EPS
N/A
N/A
Revenue
N/A
$81,391,000.00
Revenue This Year
N/A
$141.38
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
144.57
52 Week Low
$1.10
$6.62
52 Week High
$2.50
$15.35

Technical Indicators

Market Signals
Indicator
AHG
MGTX
Relative Strength Index (RSI) 57.31 54.18
Support Level $1.54 $7.21
Resistance Level $1.67 $15.35
Average True Range (ATR) 0.18 0.96
MACD 0.02 -0.16
Stochastic Oscillator 79.38 27.41

Price Performance

Historical Comparison
AHG
MGTX

About AHG Akso Health Group ADS

Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

Share on Social Networks: